Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Iovance Biotherapeutics Inc
IOVA | US
3.70
USD-0.08
-2.12%
IOVA | US
About Iovance Biotherapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/04/2026
Close
3.70
Open
3.79
High
3.91
Low
3.65
Iovance Biotherapeutics Inc. a clinical-stage biotechnology company focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies Inc. and changed its name to Iovance Biotherapeutics Inc. in June 2017. Iovance Biotherapeutics Inc. was incorporated in 2007 and is headquartered in San Carlos California.
View LessIOVA | US
Risk
83.2
Sharpe
0.14
Luna's Score
55/100
Recommendation
Hold
Luna says (IOVA | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
101.8%1 month
83.2%3 months
103.9%6 months
99.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.02
Debt to equity
0.11
Debt to assets
0.08
Ent. to EBITDA
-8.68
Ent. to rev.
84.09
PEG
-
Other Fundamentals
EBITDA
-439.25M
MarketCap
1.12B
MarketCap(USD)
1.12B
Div. yield
-
Op. margin
-327.64
Erngs. growth
-
Rev. growth
12.97K
Ret. on equity
-65.36
Short ratio
11.02
Short perc.
21.84
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.13
Range1M
1.13
Range3M
3.39
Volumes: Market Activity
Rel. volume
0.83
Price X volume
39.90M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -8.68 | - | Cheaper |
| Ent. to Revenue | 84.09 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.02 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 103.93 | - | Riskier |
| Debt to Equity | 0.11 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 1.12B | - | Emerging |
